Switch to:
Also traded in: Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.02
UHS's Cash-to-Debt is ranked lower than
97% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. UHS: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
UHS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.02 Max: 0.27
Current: 0.02
0
0.27
Equity-to-Asset 0.46
UHS's Equity-to-Asset is ranked lower than
55% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. UHS: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
UHS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.42 Max: 0.55
Current: 0.46
0.26
0.55
Debt-to-Equity 0.83
UHS's Debt-to-Equity is ranked lower than
63% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. UHS: 0.83 )
Ranked among companies with meaningful Debt-to-Equity only.
UHS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23  Med: 0.71 Max: 1.98
Current: 0.83
0.23
1.98
Debt-to-EBITDA 2.41
UHS's Debt-to-EBITDA is ranked higher than
57% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. UHS: 2.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
UHS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.32  Med: 2.4 Max: 5.39
Current: 2.41
1.32
5.39
Interest Coverage 10.44
UHS's Interest Coverage is ranked higher than
58% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. UHS: 10.44 )
Ranked among companies with meaningful Interest Coverage only.
UHS' s Interest Coverage Range Over the Past 10 Years
Min: 5.19  Med: 9.13 Max: 48.57
Current: 10.44
5.19
48.57
Piotroski F-Score: 7
Altman Z-Score: 2.50
Beneish M-Score: -2.53
WACC vs ROIC
5.55%
9.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 12.26
UHS's Operating Margin % is ranked higher than
69% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. UHS: 12.26 )
Ranked among companies with meaningful Operating Margin % only.
UHS' s Operating Margin % Range Over the Past 10 Years
Min: 7.91  Med: 13.04 Max: 13.93
Current: 12.26
7.91
13.93
Net Margin % 6.90
UHS's Net Margin % is ranked higher than
67% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. UHS: 6.90 )
Ranked among companies with meaningful Net Margin % only.
UHS' s Net Margin % Range Over the Past 10 Years
Min: 3.64  Med: 6.13 Max: 7.53
Current: 6.9
3.64
7.53
ROE % 15.14
UHS's ROE % is ranked higher than
73% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. UHS: 15.14 )
Ranked among companies with meaningful ROE % only.
UHS' s ROE % Range Over the Past 10 Years
Min: 11.67  Med: 15.9 Max: 18.6
Current: 15.14
11.67
18.6
ROA % 6.85
UHS's ROA % is ranked higher than
72% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. UHS: 6.85 )
Ranked among companies with meaningful ROA % only.
UHS' s ROA % Range Over the Past 10 Years
Min: 4.01  Med: 5.89 Max: 7.32
Current: 6.85
4.01
7.32
ROC (Joel Greenblatt) % 26.08
UHS's ROC (Joel Greenblatt) % is ranked higher than
65% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. UHS: 26.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
UHS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.97  Med: 23.03 Max: 28.88
Current: 26.08
15.97
28.88
3-Year Revenue Growth Rate 10.20
UHS's 3-Year Revenue Growth Rate is ranked higher than
62% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. UHS: 10.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
UHS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.2  Med: 10.4 Max: 19.4
Current: 10.2
-4.2
19.4
3-Year EBITDA Growth Rate 11.40
UHS's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. UHS: 11.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
UHS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.3  Med: 13.8 Max: 26.7
Current: 11.4
-3.3
26.7
3-Year EPS without NRI Growth Rate 11.60
UHS's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. UHS: 11.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
UHS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 20.5 Max: 73.8
Current: 11.6
-11.3
73.8
GuruFocus has detected 2 Warning Signs with Universal Health Services Inc UHS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» UHS's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

UHS Guru Trades in Q4 2016

Paul Tudor Jones 12,393 sh (+463.32%)
Larry Robbins 1,762,915 sh (+85.49%)
Robert Olstein 57,000 sh (+67.65%)
Jana Partners 2,051,970 sh (+61.11%)
Lee Ainslie 6,130,994 sh (+33.74%)
Vanguard Health Care Fund 4,527,240 sh (+14.92%)
Private Capital 109,139 sh (-8.42%)
Ron Baron 156,224 sh (-17.64%)
Joel Greenblatt 182,778 sh (-38.16%)
Andreas Halvorsen 350,693 sh (-81.82%)
Jim Simons 16,400 sh (-93.41%)
» More
Q1 2017

UHS Guru Trades in Q1 2017

Steven Cohen 108,830 sh (New)
Andreas Halvorsen 1,728,658 sh (+392.93%)
Jana Partners 2,449,017 sh (+19.35%)
Ron Baron 156,224 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Private Capital 107,870 sh (-1.16%)
Larry Robbins 1,714,464 sh (-2.75%)
Vanguard Health Care Fund 4,289,109 sh (-5.26%)
Lee Ainslie 4,952,724 sh (-19.22%)
Robert Olstein 41,000 sh (-28.07%)
Paul Tudor Jones 7,674 sh (-38.08%)
» More
Q2 2017

UHS Guru Trades in Q2 2017

Jim Simons 517,200 sh (New)
David Dreman 153 sh (New)
Steven Cohen 180,400 sh (+65.76%)
Paul Tudor Jones 10,825 sh (+41.06%)
Larry Robbins 1,973,545 sh (+15.11%)
Lee Ainslie 5,426,487 sh (+9.57%)
Robert Olstein 44,000 sh (+7.32%)
Andreas Halvorsen 1,742,195 sh (+0.78%)
Private Capital 107,620 sh (-0.23%)
Vanguard Health Care Fund 4,225,410 sh (-1.49%)
Ron Baron 150,734 sh (-3.51%)
Jana Partners 1,360,628 sh (-44.44%)
» More
Q3 2017

UHS Guru Trades in Q3 2017

Joel Greenblatt 78,782 sh (New)
George Soros 65,100 sh (New)
Jana Partners 1,891,986 sh (+39.05%)
Robert Olstein 56,000 sh (+27.27%)
Steven Cohen 216,100 sh (+19.79%)
Larry Robbins 2,299,484 sh (+16.52%)
Private Capital 117,580 sh (+9.25%)
Lee Ainslie 5,860,821 sh (+8.00%)
Vanguard Health Care Fund 4,354,800 sh (+3.06%)
David Dreman 153 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ron Baron 112,785 sh (-25.18%)
Andreas Halvorsen 1,193,887 sh (-31.47%)
» More
» Details

Insider Trades

Latest Guru Trades with UHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Add 3.06%0.03%$105.37 - $125 $ 113.441%4,354,800
Private Capital 2017-09-30 Add 9.25%0.17%$105.37 - $125 $ 113.441%117,580
Ron Baron 2017-09-30 Reduce -25.18%0.02%$105.37 - $125 $ 113.441%112,785
Joel Greenblatt 2017-09-30 New Buy0.13%$105.37 - $125 $ 113.441%78,782
George Soros 2017-09-30 New Buy0.22%$105.37 - $125 $ 113.441%65,100
Robert Olstein 2017-09-30 Add 27.27%0.17%$105.37 - $125 $ 113.441%56,000
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.02%$112.33 - $125.07 $ 113.44-5%4,225,410
Ron Baron 2017-06-30 Reduce -3.51%$112.33 - $125.07 $ 113.44-5%150,734
Private Capital 2017-06-30 Reduce -0.23%$112.33 - $125.07 $ 113.44-5%107,620
Robert Olstein 2017-06-30 Add 7.32%0.05%$112.33 - $125.07 $ 113.44-5%44,000
David Dreman 2017-06-30 New Buy0.01%$112.33 - $125.07 $ 113.44-5%153
Vanguard Health Care Fund 2017-03-31 Reduce -5.26%0.06%$106.71 - $126.65 $ 113.44-4%4,289,109
Private Capital 2017-03-31 Reduce -1.16%0.02%$106.71 - $126.65 $ 113.44-4%107,870
Robert Olstein 2017-03-31 Reduce -28.07%0.22%$106.71 - $126.65 $ 113.44-4%41,000
Joel Greenblatt 2017-03-31 Sold Out 0.25%$106.71 - $126.65 $ 113.44-4%0
Vanguard Health Care Fund 2016-12-31 Add 14.92%0.15%$101.55 - $128.06 $ 113.44-4%4,527,240
Joel Greenblatt 2016-12-31 Reduce -38.16%0.18%$101.55 - $128.06 $ 113.44-4%182,778
Ron Baron 2016-12-31 Reduce -17.64%0.02%$101.55 - $128.06 $ 113.44-4%156,224
Private Capital 2016-12-31 Reduce -8.42%0.18%$101.55 - $128.06 $ 113.44-4%109,139
Robert Olstein 2016-12-31 Add 67.65%0.31%$101.55 - $128.06 $ 113.44-4%57,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 622110    SIC: 8062
Compare:BKK:BDMS, NYSE:DVA, ASX:RHC, XKLS:5225, LSE:NMC, ASX:SHL, HAM:CLS1, SZSE:300015, LSE:MDC, NYSE:HLS, NYSE:MD, BKK:BH, NYSE:CHE, NYSE:EVHC, NAS:ACHC, ASX:HSO, XSGO:BANMEDICA, NSE:APOLLOHOSP, NYSE:SEM, XTER:RHK » details
Traded in other countries:UHS.Germany, UHID.USA,
Headquarter Location:USA
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers.

Universal Health Services owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers. Each segment contributes roughly half of the firm's overall revenue. Universal Health Services receives a significant portion of its net patient revenue from Medicare and Medicaid. The largest proportion of the firm's net patient revenue is paid by managed care organizations.

Ratios

vs
industry
vs
history
PE Ratio 15.58
UHS's PE Ratio is ranked higher than
81% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. UHS: 15.58 )
Ranked among companies with meaningful PE Ratio only.
UHS' s PE Ratio Range Over the Past 10 Years
Min: 8.1  Med: 15.23 Max: 23.97
Current: 15.58
8.1
23.97
Forward PE Ratio 14.01
UHS's Forward PE Ratio is ranked higher than
81% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 19.88 vs. UHS: 14.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.58
UHS's PE Ratio without NRI is ranked higher than
82% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. UHS: 15.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
UHS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.26  Med: 15.76 Max: 43.19
Current: 15.58
8.26
43.19
Price-to-Owner-Earnings 17.50
UHS's Price-to-Owner-Earnings is ranked higher than
67% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 26.22 vs. UHS: 17.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UHS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.55  Med: 16.01 Max: 412.27
Current: 17.5
7.55
412.27
PB Ratio 2.23
UHS's PB Ratio is ranked higher than
57% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 2.62 vs. UHS: 2.23 )
Ranked among companies with meaningful PB Ratio only.
UHS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.15 Max: 3.54
Current: 2.23
1.01
3.54
PS Ratio 1.08
UHS's PS Ratio is ranked higher than
67% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. UHS: 1.08 )
Ranked among companies with meaningful PS Ratio only.
UHS' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.83 Max: 1.68
Current: 1.08
0.33
1.68
Price-to-Free-Cash-Flow 22.54
UHS's Price-to-Free-Cash-Flow is ranked lower than
57% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 22.48 vs. UHS: 22.54 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UHS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.57  Med: 15.72 Max: 342.44
Current: 22.54
8.57
342.44
Price-to-Operating-Cash-Flow 10.68
UHS's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 14.62 vs. UHS: 10.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UHS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.2  Med: 8.6 Max: 24.67
Current: 10.68
3.2
24.67
EV-to-EBIT 11.99
UHS's EV-to-EBIT is ranked higher than
82% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. UHS: 11.99 )
Ranked among companies with meaningful EV-to-EBIT only.
UHS' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 11.8 Max: 26
Current: 11.99
6.2
26
EV-to-EBITDA 8.83
UHS's EV-to-EBITDA is ranked higher than
83% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. UHS: 8.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
UHS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 8.6 Max: 12.2
Current: 8.83
4.3
12.2
EV-to-Revenue 1.45
UHS's EV-to-Revenue is ranked higher than
66% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. UHS: 1.45 )
Ranked among companies with meaningful EV-to-Revenue only.
UHS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.3 Max: 2
Current: 1.45
0.5
2
PEG Ratio 1.90
UHS's PEG Ratio is ranked higher than
68% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.00 vs. UHS: 1.90 )
Ranked among companies with meaningful PEG Ratio only.
UHS' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.13 Max: 18
Current: 1.9
0.35
18
Shiller PE Ratio 23.23
UHS's Shiller PE Ratio is ranked higher than
64% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. UHS: 23.23 )
Ranked among companies with meaningful Shiller PE Ratio only.
UHS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.14  Med: 22.1 Max: 40.79
Current: 23.23
10.14
40.79
Current Ratio 1.26
UHS's Current Ratio is ranked lower than
51% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. UHS: 1.26 )
Ranked among companies with meaningful Current Ratio only.
UHS' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.41 Max: 1.98
Current: 1.26
0.95
1.98
Quick Ratio 1.16
UHS's Quick Ratio is ranked lower than
53% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. UHS: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
UHS' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.28 Max: 1.78
Current: 1.16
0.82
1.78
Days Inventory 43.10
UHS's Days Inventory is ranked lower than
75% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 16.86 vs. UHS: 43.10 )
Ranked among companies with meaningful Days Inventory only.
UHS' s Days Inventory Range Over the Past 10 Years
Min: 9.58  Med: 42.75 Max: 45.46
Current: 43.1
9.58
45.46
Days Sales Outstanding 51.74
UHS's Days Sales Outstanding is ranked lower than
67% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. UHS: 51.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
UHS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.28  Med: 53.19 Max: 62.41
Current: 51.74
42.28
62.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.35
UHS's Dividend Yield % is ranked lower than
95% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 1.63 vs. UHS: 0.35 )
Ranked among companies with meaningful Dividend Yield % only.
UHS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.17  Med: 0.42 Max: 0.99
Current: 0.35
0.17
0.99
Dividend Payout Ratio 0.05
UHS's Dividend Payout Ratio is ranked higher than
99% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. UHS: 0.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
UHS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.06 Max: 0.1
Current: 0.05
0.04
0.1
3-Year Dividend Growth Rate 26.00
UHS's 3-Year Dividend Growth Rate is ranked higher than
79% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 9.60 vs. UHS: 26.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
UHS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 58.7
Current: 26
0
58.7
Forward Dividend Yield % 0.35
UHS's Forward Dividend Yield % is ranked lower than
96% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 1.91 vs. UHS: 0.35 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.82
UHS's 5-Year Yield-on-Cost % is ranked lower than
84% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 2.24 vs. UHS: 0.82 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
UHS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.4  Med: 0.98 Max: 2.31
Current: 0.82
0.4
2.31
3-Year Average Share Buyback Ratio 0.60
UHS's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. UHS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UHS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.3  Med: 1.2 Max: 3.6
Current: 0.6
-6.3
3.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.40
UHS's Price-to-Tangible-Book is ranked lower than
88% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 3.46 vs. UHS: 10.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UHS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.04 Max: 317.57
Current: 10.4
0.84
317.57
Price-to-Intrinsic-Value-Projected-FCF 0.96
UHS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 1.98 vs. UHS: 0.96 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UHS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.72  Med: 1.16 Max: 33.96
Current: 0.96
0.72
33.96
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.59
UHS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
94% of the 36 Companies
in the Global Medical Care industry.

( Industry Median: 1.59 vs. UHS: 0.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
UHS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.35  Med: 0.75 Max: 2.42
Current: 0.59
0.35
2.42
Price-to-Median-PS-Value 1.30
UHS's Price-to-Median-PS-Value is ranked lower than
69% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. UHS: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UHS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.91 Max: 1.99
Current: 1.3
0.11
1.99
Price-to-Peter-Lynch-Fair-Value 1.72
UHS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. UHS: 1.72 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UHS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.4 Max: 3.71
Current: 1.72
0.4
3.71
Price-to-Graham-Number 2.68
UHS's Price-to-Graham-Number is ranked lower than
61% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 2.26 vs. UHS: 2.68 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UHS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.56  Med: 1.82 Max: 12.53
Current: 2.68
0.56
12.53
Earnings Yield (Greenblatt) % 8.34
UHS's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. UHS: 8.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UHS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 8.5 Max: 16.1
Current: 8.34
3.8
16.1
Forward Rate of Return (Yacktman) % 14.68
UHS's Forward Rate of Return (Yacktman) % is ranked higher than
68% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 8.93 vs. UHS: 14.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UHS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.4  Med: 18.25 Max: 30.8
Current: 14.68
4.4
30.8

More Statistics

Revenue (TTM) (Mil) $10,242.76
EPS (TTM) $ 7.28
Beta0.75
Short Percentage of Float3.28%
52-Week Range $95.26 - 129.74
Shares Outstanding (Mil)94.91

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,827 11,498 12,132
EPS ($) 7.37 8.09 8.61
EPS without NRI ($) 7.37 8.09 8.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.40 0.40 0.40

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}